Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics & Molecular Medicine, Western General Hospital, The University of Edinburgh, Edinburgh, United Kingdom.
Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Medical Research Council Institute of Genetics & Molecular Medicine, Western General Hospital, The University of Edinburgh, Edinburgh, United Kingdom.
Int J Cancer. 2019 Nov 1;145(9):2427-2432. doi: 10.1002/ijc.32550. Epub 2019 Jul 27.
Genome-wide association studies have thus far identified 130 genetic variants linked to colorectal cancer (CRC) risk (r < 0.2). Given their implication in disease causation, and thus plausible biologically effects on cancer-relevant biological pathways, we investigated whether these variants are associated with CRC prognosis and also whether they might provide predictive value for survival outcome. We conducted the analysis in a well-characterized population-based study of 5,675 patients after CRC diagnosis in Scotland. None of the genetic risk variants were associated with either overall survival (OS) or CRC-specific survival. Next, we combined the variants in a polygenic risk score, but again we observed no association between survival outcome and overall genetic susceptibility to CRC risk-as defined by common genetic variants (OS: hazard ratio = 1.00, 95% confidence interval = 0.96-1.05). Furthermore, we found no incremental increase in the discriminative performance when adding these genetic variants to the baseline CRC-survival predictive model of age, sex and stage at diagnosis. Given that our study is well-powered (>0.88) to detect effects on survival for 74% of the variants, we conclude that effects of common variants associated with CRC risk which have been identified to date are unlikely to have clinically relevant effect on survival outcomes for patients diagnosed with CRC.
全基因组关联研究迄今为止已经确定了 130 个与结直肠癌(CRC)风险相关的遗传变异(r < 0.2)。鉴于它们在疾病发病机制中的作用,以及它们对癌症相关生物学途径的潜在生物学影响,我们调查了这些变异是否与 CRC 预后相关,以及它们是否可能为生存结果提供预测价值。我们在苏格兰进行的一项针对 5675 例 CRC 确诊后患者的特征明确的基于人群的研究中进行了分析。这些遗传风险变异均与总生存期(OS)或 CRC 特异性生存期无关。接下来,我们将这些变异组合在一个多基因风险评分中,但我们仍然没有观察到生存结果与常见遗传变异定义的 CRC 风险总体遗传易感性之间存在关联(OS:风险比=1.00,95%置信区间=0.96-1.05)。此外,当将这些遗传变异添加到基于年龄、性别和诊断时分期的基线 CRC 生存预测模型中时,我们发现对生存的判别性能没有明显提高。鉴于我们的研究具有足够的效力(>0.88),可以检测到 74%的变异对生存的影响,我们得出结论,迄今为止确定的与 CRC 风险相关的常见变异的影响不太可能对诊断为 CRC 的患者的生存结果产生临床相关的影响。